title: EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bonifacio
authors.forename: Gianni
authors.initials: G
authors.lastname: Binotto
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Calistri
authors.forename: Elena
authors.initials: E
authors.lastname: Maino
authors.forename: Mario
authors.initials: M
authors.lastname: Tiribelli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000097:blood; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl